Literature DB >> 19153707

[A critical assessment of phytotherapy for prostate cancer].

F G E Perabo1, E C von Löw, R Siener, J Ellinger, S C Müller, P J Bastian.   

Abstract

Prostate cancer patients increasingly use complementary and alternative medicines to support the body's immune system in addition to conventional treatment to minimize morbidity associated with conventional treatment, to enhance the quality of life, and ultimately in the hope to cure cancer when conventional treatment fails. As there is a large variety of phytomedicines promoted as potential treatment for prostate cancer, the aim of this review was to differentiate between preventive and therapeutic approaches and evaluate which phytochemicals might be suited for therapy of prostate cancer. Therefore, preclinical in vitro and in vivo data as well as clinical trials with phytosubstances such as genistein, lycopene, epigallocatechin gallate, resveratrol, and mistletoe were assessed. The presented data show that at present there is no clinical evidence that phytochemicals might have a therapeutic use in prostate cancer in relation to reduction of tumor progression or improved survival. The question about an improved immune function or quality of life remains open. Potentially the use of phytochemicals could play a role in a preventive setting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19153707     DOI: 10.1007/s00120-008-1929-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  165 in total

Review 1.  Nutrition and prostate cancer: evidence or suspicion?

Authors:  C C Schulman; S Ekane; A R Zlotta
Journal:  Urology       Date:  2001-09       Impact factor: 2.649

2.  Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis.

Authors:  K Imaida; S Tamano; K Kato; Y Ikeda; M Asamoto; S Takahashi; Z Nir; M Murakoshi; H Nishino; T Shirai
Journal:  Carcinogenesis       Date:  2001-03       Impact factor: 4.944

3.  A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.

Authors:  E Choan; Roanne Segal; Derek Jonker; Shawn Malone; Neil Reaume; Libni Eapen; Victor Gallant
Journal:  Urol Oncol       Date:  2005 Mar-Apr       Impact factor: 3.498

Review 4.  Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.

Authors:  R Agarwal
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

5.  Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate.

Authors:  Wayne A Fritz; Jun Wang; Isam Eldin Eltoum; Coral A Lamartiniere
Journal:  Mol Cell Endocrinol       Date:  2002-01-15       Impact factor: 4.102

Review 6.  Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances.

Authors:  Y Surh
Journal:  Mutat Res       Date:  1999-07-16       Impact factor: 2.433

7.  Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer.

Authors:  T Kawamori; R Lubet; V E Steele; G J Kelloff; R B Kaskey; C V Rao; B S Reddy
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

8.  Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.

Authors:  Kedar Hastak; Sanjay Gupta; Nihal Ahmad; Mukesh K Agarwal; Munna L Agarwal; Hasan Mukhtar
Journal:  Oncogene       Date:  2003-07-31       Impact factor: 9.867

9.  Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.

Authors:  M S Ansari; N P Gupta
Journal:  Urol Oncol       Date:  2004 Sep-Oct       Impact factor: 3.498

10.  Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans.

Authors:  W Stahl; H Sies
Journal:  J Nutr       Date:  1992-11       Impact factor: 4.798

View more
  3 in total

Review 1.  [Rehabilitation of prostate cancer patients : A multidisciplinary consensus].

Authors:  Oliver Rick; J Böckmann; T Dauelsberg; W Hoffmann; W Kämpfer; U Otto; A Rogge; D Zermann
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

2.  [Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo].

Authors:  C Wehrberger; K Dreikorn; B J Schmitz-Dräger; M Oelke; S Madersbacher
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

3.  Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.

Authors:  Suresh R Volate; Brian T Kawasaki; Elaine M Hurt; John A Milner; Young S Kim; Jeffrey White; William L Farrar
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.